Keros Therapeutics Shares Outstanding 2020-2021 | KROS

Keros Therapeutics shares outstanding from 2020 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Keros Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 16
2019 2
Keros Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 23
2021-03-31 23
2020-12-31 16
2020-09-30 20
2020-06-30 18
2020-03-31 2
2019-12-31 2
2019-09-30 2
2019-06-30 2
2019-03-31 2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.719B $0.010B
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71